Introduction: Cradle cap is a very common
INTRODUCTION
Cradle cap is a form of seborrheic dermatitis that mainly manifests as thick, crusty, yellow scales on the scalp of infants and young children. It is a very common condition, usually appearing within the first 6 weeks of life and clearing spontaneously by about 6-9 months of age [1, 2] . The prevalence of cradle cap is rarely reported. According to Foley et al. [3] , the overall age-and sex-adjusted prevalence of seborrheic dermatitis in Australian preschool-aged children was 10%. A prevalence of 9.6 per 1,000 persons aged 1-5 years was reported in one study from the United States [4] . An incidence of 10% was observed for newborns in one investigation of neonatal cutaneous lesions from India [5] . Many factors including proliferation of the yeast Malassezia furfur (formerly Pityrosporum ovale), transplacental hormones and dysfunction of the sebaceous glands have been implicated in the pathogenesis of cradle cap, however, its exact etiology and pathogenesis are still unknown [2, 6, 7] . The distinction between cradle cap or infantile seborrheic dermatitis and other skin disorders such as atopic dermatitis and psoriasis can be difficult in infants. This is due to the considerable overlap of clinical features such as hyperkeratosis, inflammation, pruritus and hair loss and combined forms which may exist [8, 9] .
Distinguishing features may involve age at onset, course, distribution and pruritus. Whereas cradle cap is characterized by its early onset, mild and self-limited course, typical clinical picture, absence of itch and discomfort, atopic dermatitis is a chronic pruritic disease that may present as early as 3 months of age and due to severe itching and irritation can be extremely bothersome to the child. Psoriasis, on the other hand, is uncommon in this age group and is characterized by sharply demarcated erythematous lesions surmounted by a silvery scale [1, 2, 7, 10] .
Although cradle cap usually resolves within 6-8 weeks [11] , some cases may persist longer, and even if lasting for only a few weeks the condition worries parents because of its appearance [1] . Cradle cap may also have a bad smell. That is why caregivers generally want to act rather than wait for the condition to spontaneously resolve, even if medical treatment is usually not indicated. Although the majority of cases would require little, if any, treatment, medical intervention may be indicated in some cases. For 
Compliance with Ethics Guidelines
All procedures were followed in compliance Laboratory parameters were not monitored during the course of the study. Photographic documentation of the scalp was performed under standardized conditions (e.g., distance, illumination).
The 8-day study schedule included a baseline visit, depending on treatment success one to three control visits, and a follow-up visit. On the first day of the study, the target area, defined as the worst affected area on the scalp, was selected and its location on the scalp was The statistical analyses were performed at Bioskin using the software program SAS (Statistical analysis system (SAS) Institute Inc., Cary, USA) version 9.2 or higher. All analyses were explorative and interpreted descriptively.
The intention-to-treat (ITT) analysis was based on the full analysis set (FAS) including all subjects who received the study device at least once and had at least one post-baseline assessment. The per-protocol (PP) analysis was based on the valid cases set (VCS) including all subjects without any major violation to the study plan, who received all the doses and with available values of the primary variables at all days. All safety analyses were based on the safety evaluation set (SES) including all subjects who received the study preparation at least once.
RESULTS
A total of 20 male or female infants/children aged 3-36 months with cradle cap on the scalp (scaling score C2) were enrolled in this study, 19 of whom completed the trial. Data of all 20 subjects were valid for the SES and FAS. Nineteen subjects were included in the VCS.
One subject prematurely discontinued the investigation due to an AE (fever) on Day 2, which was assessed as unlikely related to the study preparation. Since this subject did not receive the full dose, this boy was excluded from the PP population. Demographic characteristics of the study participants are summarized in Table 2 . With regard to previous and concomitant therapies, 12 subjects were taking medication for prophylaxis of cold and 2 subjects took medication for treatment of cold.
Before treatment all subjects experienced moderate to severe scaling (moderate 80% of subjects, severe 20% of subjects). The mean scaling score at baseline was 2.2 ± 0.4.
Following treatment with the IMD, LOYON Ò , a reduction of scaling intensity was seen in the target area of the scalp skin in most of the subjects during the study course: with one to a maximum of three applications of the IMD to the total affected area of the scalp a reduction from moderate or severe to no, very mild or mild in scaling was seen in 80% of the subjects All subjects were between 3 and 36 months of age and had cradle cap on the scalp FAS full analysis set, Max maximum, Min minimum, SD standard deviation, SES safety evaluation set, VCS valid cases set (Fig. 1) . Complete resolution of scaling was noted in one subject on Day 3, in one further subject on Day 4 and in two further subjects at the follow-up visit (Day 8 ± 1). On Day 4, the mean scaling score was 1.0 ± 0.9, corresponding to a mean change from baseline of -1.2 ± 0.6.
Representative photographs showing different degrees of scalp scaling are depicted in Fig. 2 .
As shown in Fig. 3 , treatment successdefined as the reduction of the scaling baseline score by at least two points-was achieved in 50% of subjects, predominantly after 3 days of treatment: 5% of subjects had achieved treatment success on Day 2, additional 10% of subjects on Day 3 and further 35% of subjects on Day 4, yielding a time to treatment success of 1, 2 and 3 days in 5, 10 and 35% of subjects, respectively. No spot bleedings were observed at any time point during the entire study period.
No redness at the target area was noted in any subject at baseline; after treatment with the IMD, moderate redness was observed in two subjects (in one subject on Days 2 and 4 and in another subject on Day 3) and very mild to mild redness at the target area occurred in most subjects during the study period, with the largest percentage (75%) occurring on Day 4
( Fig. 4) . At the follow-up visit resolution of redness was observed in 53% of the subjects.
The results recorded by the investigators are in agreement with the positive treatment evaluations by the parents/legal guardians.
According to the judgment by most parents/ legal guardians the product is easy to apply (90% of parents/legal guardians), has a comfortable consistency (80%) and brings about a significant improvement of skin appearance (85%). 70% of them were satisfied with the improved skin appearance in their children, with 20% experiencing this as positively affecting the relationship to their child. In one subject, an unpleasant odor of the affected skin had been noted at baseline which improved with treatment. Overall treatment with the IMD was rated as 'good'.
Regarding safety, a total of seven non-serious
AEs of mild to moderate intensity were reported in five subjects (Table 3) . Two AEs concerned itching and were assessed as probably related to the study preparation and the procedure. In a Fig. 1 Clinical assessment of scaling during the study course. The target area of the scalp was scored for scaling on Day 1 (baseline), and after treatment on Day 2, on Days 3 and 4 in case of no treatment success on an earlier day and on Day 8 using the scale shown in Table 1 further child, soft yellow crusts with tiny vesicles and no signs of infection or pruritus at the application area were noted. This AE was assessed as possibly related to the study preparation, with the investigator suggesting an accumulation of sweat under the crust. The other four AEs (cold with fever, fever, rhinitis and conjunctivitis) were considered as unlikely related to the study preparation. Whereas five
AEs had resolved at the end of the study, two AEs [cold with fever and fever (dropout on Day
2)] were still ongoing on Day 8, follow-up by phone revealed that both affected subjects had made a full recovery. There were no device deficiencies recorded during the study.
DISCUSSION
As opposed to conventional treatments for cradle cap that often contain salicylic acid, steroids or antimycotics, the IMD (LOYON Ò )
does not contain any pharmacologically active Indeed, treatment with the IMD reduced scaling of the scalp skin in most of the infants or children with cradle cap and the onset of effect was rapid: an improvement was already observed after one to three administrations. A reduction from at least moderate scaling to mild scaling or less was noted in 80% of subjects. Concurrently, very mild to mild redness was noted in most of the subjects during the study period, i.e., in 75% of subjects on Day 4. The presence of the two clinical findings, improvement in scaling and appearance of mild redness, favors the occurrence of mild redness as being due to the removal of scales rather than due to irritation. In more than half of the subject, redness had disappeared at the follow-up visit on Day 8 ± 1. A treatment success, i.e., reduction in scaling intensity by at least two points, was achieved in half of the subjects. This treatment success occurred after only one or two applications in some subjects and was generally reached after Itching, which occurred in two subjects, was assessed as probably related to the study preparation and procedure. Overall, the IMD appears to be well tolerated in infants and young children. Specific risks were not observed.
There are several limitations of this study. First, this study involved only a limited sample size of 20 subjects. Yet, the main intention of this study was proof-of-concept and corresponding studies are usually small and obtained data may not be complete. Second, the study period was rather short and the number of applications limited. As for safety, specific risks were not observed with short-term use and, considering the composition and mode With regard to efficacy, treatment duration with only three applications was sufficient to achieve rapid improvement in 80% of the study participants. Third, this study lacked a comparator group. However, there are no official guidelines on cradle cap and a generally accepted reference treatment does not exist. Since cradle cap usually lasts a few weeks or months until it clears by itself it seems very unlikely that cradle cap improved spontaneously in all of the treatment responders (15 of 20 subjects) during the three study days. Therefore, the obtained improvement in scaling is not considered an incidental finding but a result of treatment.
Thus, the aim of this study has been reached, i.e., the demonstration of the feasibility of using the IMD as an effective and safe treatment option in cradle cap. 
